IL1A and depressive disorder: In this study, we found that the CMS protocol increased Iba1 expression as well as TNF-α, IL-1α, and IL-1β levels in the hippocampus or serum, while MOs successfully inhibited this effect in CMS-exposed mice, leading to the attenuation of depression-like symptoms.